Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding… Continue reading Efficacy and safety of #metformin versus #empagliflozin on chronic #kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
Tag: empaglifozin
#Empagliflozin and the Risk of #Retinopathy in Patients With Type 2 Diabetes
Question Is there an association between empagliflozin and the risk of nonproliferative diabetic retinopathy (NPDR) and diabetic retinopathy (DR) progression in patients with type 2 diabetes (T2D)?Findings In this cohort study, there was no association between empagliflozin and incident NPDR in patients with T2D who had no DR history; however, empagliflozin was associated with a… Continue reading #Empagliflozin and the Risk of #Retinopathy in Patients With Type 2 Diabetes
2 Medical News 